What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

Core Insights - Pfizer Inc. is set to conduct an investor call to provide full-year 2025 financial guidance, with Goldman Sachs outlining expectations for the guidance and commentary on the upcoming year [1] - The analyst anticipates Pfizer's management will guide to EPS in the mid-to-high $2 range, with core business growth offset by $0.30 in favorable but non-recurring items during 2024 [1] Financial Projections - Pfizer's 2024 EPS includes one-time boosts such as a $1.2 billion benefit from Paxlovid stockpiling and U.S. government true-up, which will not carry over to 2025 due to a decrease in ownership in Haleon Plc [2] - Goldman Sachs forecasts 2025 revenues of $64.9 billion and EPS of $3.13, compared to consensus estimates of $63.2 billion and $2.89, respectively [2] Sales Expectations - The impact of the IRA Part D redesign is expected to be addressed in the 2025 guidance, though details may not be broken down by individual products [3] - Expected Paxlovid sales for 2025 are projected at $4.3 billion, exceeding consensus of $3.7 billion, while Vyndaqel sales are forecasted at $5.9 billion, slightly below consensus of $6.2 billion [3] Market Performance - Eliquis has shown 12% growth year-to-date, supported by market expansion and increased market share, with expectations for continued growth opportunities in 2025 [4] - Pfizer's commercial team has played a significant role in this growth, aided by Part D catastrophic coverage in 2024 [4] Industry Context - Goldman Sachs highlights that Pfizer is the only large-cap pharma company expected to provide insights on 2025 ahead of the new year, indicating potential broader implications for the industry [5] Stock Performance - As of the latest check, PFE stock is down 0.39% at $25.48 [6]